MedTrace Logo

Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

NCT05320159 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17743

Last updated 2022-07-01

No results posted yet for this study

Summary

This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.

Conditions

Interventions

DRUG

Secukinumab

Included all the patients treated with secukinumab

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-03
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05320159 on ClinicalTrials.gov